Skip to main content

Kathleen M. Neuzil, MD, MPH, FIDSA

Myron M. Levine, MD, DTPH Professor of Vaccinology

Academic Title:


Primary Appointment:


Secondary Appointment(s):


Administrative Title:

Division Head, Geographic Medicine; Director for the Center for Vaccine Development and Global Health

Additional Title:

Myron M. Levine, MD, DTPH Professor in Vaccinology and Director, Center for Vaccine Development and Global Health


HSF I 480G

Phone (Primary):




Education and Training

  • University of Maryland (summa cum laude), B.S., Zoology, 1983
  • Johns Hopkins University School of Medicine (Alpha Omega Alpha (AOA) Honor Medical Society), 1987
  • Residency, Vanderbilt University School of Medicine, Internal Medicine, 1987-1991
  • Fellowship, Vanderbilt University School of Medicine, Infectious Diseases, 1991-1994
  • Vanderbilt University School of Medicine, M.P.H., 1998


Kathleen Neuzil is the Myron M. Levine Professor in Vaccinology, Professor of Medicine and Pediatrics, and the Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. She is an internationally recognized research scientist and advocate in the field of vaccinology.

Throughout her career, Dr. Neuzil has conducted clinical and epidemiologic studies on vaccine-preventable diseases. Dr. Neuzil’s work has spanned dozens of countries with multiple vaccines, including influenza, rotavirus, human papillomavirus, Japanese encephalitis, typhoid conjugate vaccines, and most recently, COVID-19 vaccines. She has more than 230 scientific publications on vaccines and infectious diseases.

Dr. Neuzil's research capabilities are complemented by 20 years of involvement in domestic and international vaccine policy, including past membership on the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. She is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization and is a member of the National Academy of Medicine.



Research/Clinical Keywords

Global public health, infectious diseases, vaccine access and delivery, vaccine safety, rotavirus, pandemic influenza, immunization, maternal immunization, diarrheal diseases, maternal child health, reproductive health, sexually transmitted diseases, COVID-19, vaccinology, human papillomavirus, Japanese encephalitis, typhoid conjugate vaccines, TyVAC

Highlighted Publications

Ortiz JR, Spearman PW, Goepfert PA, Cross K, Buddy Creech C, Chen WH, Parker S, Overton ET, Dickey M, Logan HL, Wegel A, Neuzil KM. Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. Vaccine. 2022 May 20;40(23):3253-3262. doi: 10.1016/j.vaccine.2022.03.055. Epub 2022 Apr 22. PMID: 35465983.

Birger R, Antillón M, Bilcke J, Dolecek C, Dougan G, Pollard AJ, Neuzil KM, Frost I, Laxminarayan R, Pitzer VE. Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. Lancet Infect Dis. 2022 May;22(5):679-691. doi: 10.1016/S1473-3099(21)00627-7. Epub 2022 Feb 3. PMID: 35123673; PMCID: PMC9021026.

Edwards KM, Neuzil KM. Understanding COVID-19 through human challenge models. Nat Med. 2022 May;28(5):903-904. doi: 10.1038/s41591-022-01778-3. PMID: 35361993.

Sparrow E, Adetifa I, Chaiyakunapruk N, Cherian T, Fell DB, Graham BS, Innis B, Kaslow DC, Karron RA, Nair H, Neuzil KM, Saha S, Smith PG, Srikantiah P, Were F, Zar HJ, Feikin D. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use. Vaccine. 2022 Jun 9;40(26):3506-3510. doi: 10.1016/j.vaccine.2022.02.040. Epub 2022 Feb 17. PMID: 35184927; PMCID: PMC9176315.

Henschke N, Bergman H, Hungerford D, Cunliffe NA, Grais RF, Kang G, Parashar UD, Wang SA, Neuzil KM. The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality. Vaccine. 2022 Mar 15;40(12):1707-1711. doi: 10.1016/j.vaccine.2022.02.003. Epub 2022 Feb 17. PMID: 35184924; PMCID: PMC8914343.

Research Interests

Dr. Neuzil's research focuses on vaccine development and introduction in under-developed areas. She works on a variety of vaccines, including influenza, typhoid, and COVID-19, as well as on cross-cutting issues such as maternal immunization, optimizing vaccine use, and overcoming barriers to sustainable vaccine uptake in low resource settings. Dr. Neuzil is central to the domestic and global response to COVID-19.

Her capabilities range from epidemiology and clinical trials to expertise in vaccine research and development, partnerships with vaccine manufacturers, and domestic and international health policy.

Awards and Affiliations

  • The Myron M. Levine, MD Professorship in Vaccinology (Endowed Professorship), University of Maryland School of Medicine, 2019
  • National Academy of Medicine; Member 2019-present
  • Chair, Pandemic Influenza Task Force, Infectious Disease Society of America (IDSA) 2005-2008; Member 2008-present
  • Member, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, 2006-2010 (Chair, Influenza Vaccine Working Group, 2008-2010; Chair, Vaccines in Pregnancy Working Group 2006-2008)
  • PATH Vision Award in the Advancing Global Health Category for the Cervical Cancer Prevention Project, 2009
  • Joseph E. Smadel lectureship, IDSA Annual Meeting, Vancouver, CA, 2010
  • Member of the World Health Organization Strategic Advisory Group of Experts on Immunization
  • 2020 Baltimore Sun Marylander of the Year Awardee
  • 2020 Fierce Pharma "The 22 Most Influential People in the Fight Against COVID-19"
  • 2021 Sonia Skarlatos Public Service Award from the American Society of Gene & Cell Therapy
  • 2021 Annual Boy Scouts of Central Maryland Health Services Leadership Award for Outstanding Service
  • VRC Scientific Advisory Panel, NIH, 2020 - Present
  • WHO Department of Immunization, Vaccine & RSV Biologicals Technical Advisory Group, 2020 - Present
  • Co-Director of COVID-19 Prevention Network, 2020 - Present
  • Member Advisory Group for the Global Typhoid Genomics Consortium, 2021 - Present
  • Senior Advisor to the Global Virus Network (GVN), 2021 - Present
  • Member BactiVac Network Adivsory Board, 2021 - Present

Grants and Contracts

11/01/21 – 10/31/25 (PI)
“Accelerating Access to Typhoid Conjugate Vaccines” (TyVAC 2.0)
Sponsor: Bill and Melinda Gates Foundation

09/11/17-06/30/2022 (Protocol PI)
“A Phase II Trial to Evaluate the Safety, Immunogenicity, and Efficacy of a Single Dose of Tdap on Infant Immune Responses in Pregnant Women in a Low-Middle Income Country”
NIAID Vaccine Treatment and Evaluation Unit, 16-0024

07/01/18-06/30/23 (Contact PI)
“Fellowship Training Program in Vaccinology” T32 Grant
National Institute of Allergy and Infectious Disease (NIAID), T32AI007524

09/16/19-09/15/26 (Contact PI)
“Collaborative Influenza Vaccine Innovation Centers (CIVICs) Component C: Clinical Core”
National Institute of Allergy and Infectious Disease (NIAID), 75N93019C00055

12/05/19-11/30/26       (Co- PI, Multi-PI Award) Contact PI: David Stephens, Emory
“Leadership Group for Infectious Diseases Clinical Research Consortium (IDCRC)”
NIH, NIAID, 1UM1AI148684-01

In the News

Dr. Neuzil is regularly interviewed and quoted as a vaccine expert.

Recent news includes:

Professional Activity

Dr. Kathleen Neuzil have over 25 years of experience in infectious diseases and vaccine science, policy & leadership. Her capabilities range from proficiency in epidemiology and clinicals trials to expertise in vaccine research & development, partnerships with developing country vaccine manufacturers, & knowledge & experience with domestic & international regulatory practices. Dr. Neuzil's vaccine research on influenza, rotavirus, pertussis, and typhoid vaccines, among others, has advanced science and influenced policy. These studies have ranged from designing and executing Phase 1 trials to leading pivotal clinical trials, including large multicenter field studies and cluster-randomized trial. 

Based on Dr. Neuzil's broad influenza and vaccine experience, she was selected as co-director of the Coronavirus Prevention Network (CoVPN), a network of NIH-funded sites who participated in the US-supported Phase 3 trials of Covid-19 vaccines.  As such, she is part of the strategic team evaluating COVID vaccines and therapeutics in the US, being involved in the conception, design, execution, analysis, and interpretation of these studies. She serves as an ad hoc member of the ACIP working group on SARS-CoV-2 vaccines, and as a scientific advisor for the Oxford University on their ChimpAd vectored-coronavirus vaccine program. As a member of SAGE, she advises the WHO on use of COVID-19 vaccines as data become available.

Dr. Neuzil's research and leadership capabilities are complimented by over two decades of involvement in domestic & international vaccine policy, including membership on CDC’s Advisory Committee on Immunization Practices (ACIP) and past & current advisory positions on World Health Organization (WHO) vaccine policy committees.  She is currently a member of the WHO Strategic Advisory Group of Experts on Immunization (SAGE).

Dr. Kathy Neuzil has a strong commitment to mentoring the next generation of vaccine scientists & leaders. This includes formal academic mentorship & participation on masters & PhD dissertation committees. She currently serves as Contact PI (Multi PI mechanism) of the University of Maryland School of Medicine Center for Vaccine Development and Global Health's NIAID T32 Training Grant in Vaccinology, as a mentor on K01 Awards. Beyond these specific trainee-focused grants, Dr. Neuzil works with trainees at all levels in my research. As PI or Co-PI of large multicenter initiatives funded by NIH & the Gates Foundation, she actively seeks opportunities for trainees.